[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614038":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":55,"collaborators":57,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":20,"enrollmentInfo":69,"targetDuration":20,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Beta Emitting Accurate Monitored Systems","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Early post-operative PET-MRI group","OTHER","Participants in this arm will undergo early post-operative PET-MRI imaging within 48 hours after surgical resection of a suspected glioblastoma. The imaging procedure includes a brain MRI with gadolinium-based contrast and a PET scan using 18F-DOPA as the radiotracer. Patients will be monitored for potential adverse events related to the imaging agents and for radiation exposure. No therapeutic intervention will be administered. The purpose of this diagnostic intervention is to assess feasibility, safety, and imaging performance in detecting residual tumor tissue.",[13],"Diagnostic Test: Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium","This intervention consists of a combined brain PET-MRI imaging session performed within 48 hours after surgical resection of a suspected glioblastoma. The PET scan uses 18F-DOPA as the radiotracer, administered intravenously at a dose of 2 MBq\u002Fkg, with static brain acquisition starting immediately post-injection. The MRI includes standard sequences and gadolinium-based contrast-enhanced imaging. The goal is to assess the feasibility and safety of this early post-operative imaging procedure, and to validate imaging parameters for the detection of residual tumor. Radiation dosimetry and potential adverse events related to imaging agents will be monitored.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Caroline Apra, MD, PhD","CONTACT","+330149812240","contact@beams.bio",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Nawel Saci, Msc","+33667405900","nawelsaci@olexclinical.com",[32],{"facility":33,"status":34,"city":35,"state":20,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Hôpital Henri Mondor - Université Paris-Est Créteil (UPEC)","RECRUITING","Créteil","94010","France","FR",{"type":40,"coordinates":41},"Point",[42,43],2.46569,48.79266,{"lat":43,"lon":42},[46,50,52],{"name":47,"role":24,"phone":48,"phoneExt":20,"email":49},"Virginie Simon","+33 149812240","virginie.simon@beams.bio",{"name":51,"role":24,"phone":29,"phoneExt":20,"email":30},"Nawel SACI",{"name":53,"role":54,"phone":20,"phoneExt":20,"email":20},"Caroline Apra","PRINCIPAL_INVESTIGATOR",{"type":56,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[58],{"name":59,"class":10},"Assistance Publique - Hôpitaux de Paris","100614038","assessment-of-early-post-operative-nuclear-imaging-in-neurosurgery-a-safety-and-feasibility-study-in-patients-operated-for-glioblastoma-100614038",false,"NCT07274397","Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma","EARLYBRAINPET","Inclusion Criteria:\n\n* First resection for a suspected glioblastoma in the past 72h\n* Signed informed consent\n\nnon-inclusion Criteria:\n\n* Deprived of liberty or under legal protection (e.g, guardianship, trusteeship)\n* Patients under 18 years old\n* Absence of social security cover\n* Pregnancy\n* Emergency procedure\n* Contraindication to brain MRI, including claustrophobia\n* Contraindication to radiotracers or gadolinium injection\n* Preoperative cognitive impairment impeding patient information\n\nExclusion criteria :\n\n* Any postoperative behavioral disorders or medical condition or symptom impeding the completion of brain imaging\n* Postoperative medical dependency impeding the patient transfer to the nuclear medicine department (including, but not limited to, invasive ventilation, need for external ventricular drainage…)\n* Postoperative histological diagnosis different from glioblastoma","ALL","18 Years",{"count":70,"type":71},15,"ESTIMATED","INTERVENTIONAL",[74],"NA","This clinical trial aims to evaluate the feasibility and safety of early post-operative brain PET-MRI imaging in adult patients who have undergone surgery for suspected glioblastoma. The study also seeks to validate specific nuclear imaging parameters for better detection of residual tumor tissue compared to standard gadolinium-enhanced MRI. The main objectives are to determine whether early PET-MRI within 48 hours post-surgery is feasible, to assess potential side effects related to imaging procedures, and to explore if PET parameters such as SUVmax, metabolic volume, and tumor-to-striatum ratio can improve the detection of tumor residue. A total of 15 patients will be included at a single site in France. Participants will undergo PET-MRI using 18F-DOPA and gadolinium, and will be monitored for radiation exposure and possible adverse events up to 24 hours after imaging.",[77,78,79],"Glioblastoma","Brain Tumors","Brain Imaging",[77,81,82,83,84,85,86],"brain tumors","PET-MRI","18F-DOPA","Radiotracer","Diagnostic Imaging","Nuclear Medicine","2026-06-05",{"date":89,"type":90},"2026-06-08","ACTUAL",{"date":92,"type":90},"2026-04-17",{"date":94,"type":71},"2027-04-17",{"name":5,"class":6},1]